Alembic Pharmaceuticals Limited

BSE:533573 Stock Report

Market Cap: ₹206.3b

Alembic Pharmaceuticals Management

Management criteria checks 1/4

Alembic Pharmaceuticals' CEO is Chirayu Amin, appointed in Apr 2016, has a tenure of 8.67 years. total yearly compensation is ₹193.80M, comprised of 48.4% salary and 51.6% bonuses, including company stock and options. directly owns 2.13% of the company’s shares, worth ₹4.40B. The average tenure of the management team and the board of directors is 1.5 years and 9.8 years respectively.

Key information

Chirayu Amin

Chief executive officer

₹193.8m

Total compensation

CEO salary percentage48.4%
CEO tenure8.7yrs
CEO ownership2.1%
Management average tenure1.5yrs
Board average tenure9.8yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Chirayu Amin's remuneration changed compared to Alembic Pharmaceuticals's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

₹6b

Jun 30 2024n/an/a

₹6b

Mar 31 2024₹194m₹94m

₹6b

Dec 31 2023n/an/a

₹6b

Sep 30 2023n/an/a

₹5b

Jun 30 2023n/an/a

₹5b

Mar 31 2023₹88m₹88m

₹3b

Dec 31 2022n/an/a

₹2b

Sep 30 2022n/an/a

₹3b

Jun 30 2022n/an/a

₹3b

Mar 31 2022₹280m₹80m

₹5b

Dec 31 2021n/an/a

₹8b

Sep 30 2021n/an/a

₹9b

Jun 30 2021n/an/a

₹10b

Mar 31 2021₹315m₹65m

₹11b

Dec 31 2020n/an/a

₹12b

Sep 30 2020n/an/a

₹11b

Jun 30 2020n/an/a

₹10b

Mar 31 2020₹265m₹65m

₹8b

Dec 31 2019n/an/a

₹7b

Sep 30 2019n/an/a

₹7b

Jun 30 2019n/an/a

₹6b

Mar 31 2019₹255m₹55m

₹6b

Dec 31 2018n/an/a

₹6b

Sep 30 2018n/an/a

₹5b

Jun 30 2018n/an/a

₹4b

Mar 31 2018₹220m₹55m

₹4b

Compensation vs Market: Chirayu's total compensation ($USD2.27M) is above average for companies of similar size in the Indian market ($USD580.77K).

Compensation vs Earnings: Chirayu's compensation has increased by more than 20% in the past year.

CEO

Chirayu Amin (78 yo)

8.7yrs

Tenure

₹193,800,000

Compensation

Mr. Chirayu Ramanbhai Amin, M.B.A. (U.S.A.), has been Chief Executive Officer of Alembic Pharmaceuticals Limited since April 27, 2016. Mr. Amin served as Managing Director of Alembic Pharmaceuticals Limite...

Leadership Team

NamePositionTenureCompensationOwnership
Chirayu Amin
Executive Chairman & CEO8.7yrs₹193.80m2.13%
₹ 4.4b
Pranav Amin
Managing Directorless than a year₹190.90m0.59%
₹ 1.2b
Shaunak Amin
MD & Executive Director9.7yrs₹122.20m0.51%
₹ 1.1b
Raj Kumar Baheti
Director of Financeno data₹56.90mno data
Sudhakar Pandiyan
Head of Technical Operationsless than a yearno datano data
J. Raman
Chief Scientific Officerno data₹8.41mno data
Manisha Saraf
Company Secretary & Compliance Officer1.7yrsno datano data
Udit Amin
Chief Business Development Officerno data₹8.30m0.51%
₹ 1.1b
Gautam Chatterjee
Senior Vice Presidentno data₹8.12mno data
Ajay Desai
Senior Vice President of Financeno data₹9.20mno data
Shreekumar Nair
Senior Vice President of Supply Chainno datano datano data
Nilesh Wadhwa
Head of International Business & Strategy1.3yrsno datano data

1.5yrs

Average Tenure

63yo

Average Age

Experienced Management: 533573's management team is not considered experienced ( 1.5 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Chirayu Amin
Executive Chairman & CEO14.5yrs₹193.80m2.13%
₹ 4.4b
Shaunak Amin
MD & Executive Director11.6yrs₹122.20m0.51%
₹ 1.1b
Raj Kumar Baheti
Director of Finance14.5yrs₹56.90mno data
Archana Hingorani
Independent Non-Executive Director9.8yrs₹2.28mno data
Manish Kejriwal
Independent Directorless than a yearno datano data
Ashok Barat
Independent Director2.8yrs₹1.82mno data
Jai Diwanji
Independent Director1.6yrs₹2.10mno data

9.8yrs

Average Tenure

59yo

Average Age

Experienced Board: 533573's board of directors are considered experienced (9.8 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/29 02:44
End of Day Share Price 2024/12/27 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Alembic Pharmaceuticals Limited is covered by 25 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Sarabjit NangraAngel Broking Private Limited
null nullAntique Stockbroking Ltd.
Harith AhamedAvendus Spark